Cargando…

Biosimilars as a strategy to improve sustainability

Detalles Bibliográficos
Autores principales:	Bria, Emilio, Conte, Pierfranco
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2017
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5703382/ https://www.ncbi.nlm.nih.gov/pubmed/29259817 http://dx.doi.org/10.1136/esmoopen-2017-000192

Ejemplares similares

Biosimilars
por: Martin, Miguel
Publicado: (2018)

Biosimilar insulin concepts
por: Bloomgarden, Zachary T.
Publicado: (2022)

The Development Pathway for Biosimilar Biotherapeutics
por: Zarbin, Marco
Publicado: (2020)

Here to Stay: Biosimilars in Hematology
por: Gribben, John, et al.
Publicado: (2019)

Biologics and biosimilars: what, why and how?
por: Chan, Juliana CN, et al.
Publicado: (2017)

Therapeutic Monoclonal Antibodies and Emergence of Their Biosimilars
por: Jeddi-Tehrani, Mahmood
Publicado: (2018)

Biosimilars: Promises Made. Promises Kept?
por: Martinez-Cabriales, Sylvia A., et al.
Publicado: (2021)

There Is No Substitute for Effective Education About Biosimilars
por: Maltz, Ross M, et al.
Publicado: (2021)

Rituximab biosimilars open new horizons in immunotherapy
por: Jaeger, Ulrich
Publicado: (2017)

Biosimilar, biobetter and next generation therapeutic antibodies
Publicado: (2011)

Biosimilar insulins: Informed choice for South Asia
por: Kalra, Sanjay, et al.
Publicado: (2016)

Fármacos biológicos y biosimilares: aclarando conceptos
por: Rodriguez Cumplido, Dolores, et al.
Publicado: (2018)

Biosimilars: To switch or not to switch – that is the question
por: Szekanecz, Zoltán
Publicado: (2020)

Expanding Footprints of Biosimilar Tenecteplase
por: Subhash, et al.
Publicado: (2023)

Biosimilars: Review of current applications, obstacles, and their future in medicine
por: Kaida-Yip, Flyn, et al.
Publicado: (2018)

Why are biosimilars much more complex than generics?
por: Pagani, Eduardo
Publicado: (2019)

Biosimilar FSH preparations- are they identical twins or just siblings?
por: Orvieto, Raoul, et al.
Publicado: (2016)

Emerging Insights into European Markets of Biologics, Including Biosimilars
por: Simoens, Steven, et al.
Publicado: (2022)

Extrapolation concept at work with biosimilar: a decade of experience in oncology
por: Krendyukov, Andriy, et al.
Publicado: (2018)

Considerations for the US health-system pharmacist in a world of biosimilars
por: Zlatkus, Andrea, et al.
Publicado: (2020)

An international comparative analysis and roadmap to sustainable biosimilar markets
por: Alnaqbi, Khalid A., et al.
Publicado: (2023)

Are biosimilars the next tool to guarantee cost-containment for pharmaceutical expenditures?
por: Farfan-Portet, María-Isabel, et al.
Publicado: (2013)

From Biologics to Biosimilars and Biobetters – Democratization of High-end Therapeutics
por: Honavar, Santosh G
Publicado: (2021)

Can we establish a hierarchy among trastuzumab biosimilar candidates?
por: Pivot, Xavier, et al.
Publicado: (2018)

Addressing unmet clinical needs: the potential of biosimilars in the treatment of rheumatic diseases
por: Schulze-Koops, Hendrik
Publicado: (2017)

Approval of the first biosimilar antibodies in Europe: A major landmark for the biopharmaceutical industry
por: Beck, Alain, et al.
Publicado: (2013)

An Integrated Approach for a Structural and Functional Evaluation of Biosimilars: Implications for Erythropoietin
por: Gianoncelli, Alessandra, et al.
Publicado: (2015)

European Stakeholder Learnings Regarding Biosimilars: Part I—Improving Biosimilar Understanding and Adoption
por: Barbier, Liese, et al.
Publicado: (2020)

The ESMO position paper on biosimilars in oncology: enhancing the provision of accurate education and information
por: Schiestl, Martin, et al.
Publicado: (2017)

Phase 3 LILAC study sets standard for clinical evaluation of oncology biosimilars
por: Kolberg, Hans-Christian, et al.
Publicado: (2019)

Biosimilars; a unique opportunity for Iran national health sector and national pharmaceutical industry
por: Cheraghali, Abdol Majid
Publicado: (2012)

Journey of a therapeutic poison: Botulinum toxin A and its biosimilars
por: Bhattacharjee, Kasturi, et al.
Publicado: (2021)

European Stakeholder Learnings Regarding Biosimilars: Part II—Improving Biosimilar Use in Clinical Practice
por: Barbier, Liese, et al.
Publicado: (2020)

Sustainability of Biosimilars in Europe: A Delphi Panel Consensus with Systematic Literature Review
por: Vulto, Arnold G., et al.
Publicado: (2020)

A new peg-filgrastim biosimilar, mecapegfilgrastim for primary prophylaxis of chemotherapy-related neutropenia is now available
por: Tirelli, Umberto, et al.
Publicado: (2020)

Improving Access to Cancer Treatments: The Role of Biosimilars
por: Chopra, Rakesh, et al.
Publicado: (2017)

European medicines agency guideline for biological medicinal products: a further step for a safe use of biosimilars
por: Agostini, Carlo, et al.
Publicado: (2015)

Strategies for editors to contribute for the achievement of the Sustainable Development Goals by 2030
por: Nassi-Calò, Lilian
Publicado: (2023)

Biosimilar-to-Biosimilar Switching: What is the Rationale and Current Experience?
por: Mysler, Eduardo, et al.
Publicado: (2021)

Challenges of modern day transition care in inflammatory bowel disease: From inflammatory bowel disease to biosimilars
por: Hakizimana, Ali, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_7lh1kk3knuiaof7lqggs6klk3c